Welcome to the Ministry of Foreign Affairs

Transcription

1 Welcome to the Ministry of Foreign Affairs

2 National Experimental Therapy Partnership (NEXT) NEXT is a public-private partnership within clinical research offering a one stop shop for the pharmaceutical industry and for researchers.

3 Clinical Trials Office Denmark Clinical Trials Office Denmark works to attract more clinical trials to Denmark. The office offers a number of services and assists with access to the Danish healthcare system.

4 Statens Serum Institut A public enterprise under the Danish Ministry of Health with over 100 years of experience Center for Disease Control (CDC) of Denmark SSI s main task is disease control and to secure the preparedness towards infectious diseases and congenital disorders in Denmark and internationally Also, SSI is one of the major international research institutions in Denmark with a staff of more than 700. Based in Copenhagen. Holds more patents than all Danish universities combined Denmark s National Biobank One of the world s largest biobank registers and physical biobanks with more than 22 million samples Coordinating Centre connecting to scientists and external biobanks in all of Denmark

5 Novo Nordisk HQ in Denmark, employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Core areas: Diabetes, obesity, haemophilia, and relevant co-morbidities. Novo Nordisk R&D engages in partnerships with universities and biotech companies globally. Collaborate with global top universities on PhD and post doc programmes to help foster/develop next generation of to researchers withing their focus areas.

6 Copenhagen University One of the largest institutions of research and education in the Nordic countries with 90,000 students and a staff of more than 9,000. Healthcare research is undertaken across the biomedical, natural and social sciences. Close relationship with public-sector and private-sector stakeholders for an innovation cycle with implementation of early diagnostics, prevention and treatment of human and veterinary diseases including personalised treatment and drug development.

7 Accelerace Accelerace is a Denmark-based internationally focused business development organization. They spot, train and fund start-up talents. They run international accelerator programs with leading corporate partners. Also, they work as a trusted advisor to established companies to build innovation strategies that support successful corporate startup engagement and cultural change.

8 Life Sciences in Denmark World class research, skilful companies, visionary universities, and an effective public health care sector has secured an innovative Life Science environment in Denmark and developed an ideal location for international companies 27 April, 2017

9 Life Sciences in Denmark 6 new super hospitals & university hospitals with specialized units 21 hospitals with specialized departments and acute care 8 universities High concentration of companies in Denmark 9 science parks 6 science incubators

10 # per mio. inhabitans Number of pharmaceutical and biotech companies 2,5 2 1,5 1 0,5 0 Danmark Sverige Irland UK Finland Belgium Frankrig Holland Tyskland 10 Source: Pharma, 2015

11 Overall Framework Conditions Government has highly prioritised the health & life science sector for several years Business conditions very consistent and transparent for corporates & start-ups alike 6 new super hospitals and 21 hospitals with specialized departments and acute care Strong knowledge base of human capital provides companies with highly competent staff Denmark has national biobanks and data registries established more than 50 years ago, combined with unparalleled conditions for running clinical trials (CPR number system, high retention and participation rates, etc) Venture capital & start-up financing

12 Denmark from an international perspective Denmark has the largest commercial drug development pipeline in Europe (Ernst and Young, 2015) Denmark is ranked the best country in Europe for development of biotechnology. (Scientific American, 2016) Denmark is one of the most R&D intense countries worldwide, and the best in Europe regarding researcher concentration (Bloomberg Innovation Index, 2016) Denmark has the world greatest percentage of patents in biotechnology. (Scientific American, 2016) Denmark has the second strongest perceived entrepreneurship climate in the world, only exceeded by Sweden. (Scientific American, 2016)

13 Strong pharma/biotech hub of established players...

14 .and Stars of the future

15 EUR per inhabitants Pharmaceutical and biotech investments in R&D Danmark UK Tyskland Frankrig Belgium Irland Sverige Source: Pharma, 2015

16 25 Denmark has the strongest drug development pipeline in Europe Number of drugs in development per capita (Source: Ernst & Young, Beyond borders 2015)

17 Billion DKK Denmark is among the largest exporters per capita of pharmaceutical products Development in Danish drug export (Source: Statistics Denmark,

18 Life Science Centres in Denmark Science Parks Innovation Incubators University Hospitals

19 Universities and Research Centers Life Sciences

20 Denmark & Medicon Valley 27 April, 2017

21 Medicon Valley one of Europe s strongest life science clusters

22 Danish Cancer Society NN Center for Metabolic Research Statens Serum Institute National Allergy Center BRIC Steno Diabetes Center Sino- Danish Breast Cancer Research Center for Inflammatio n and Metabolism Research Centers Hagedorn Research Institute NN Center for Protein Research NN Center for Biosustainability Biobanks Symbion Copenhagen University Science parks SCION DTU CAT Science Park DTU Technical University Universities COBIS Lund University University Hospitals Clinical Unit Rigshospital Hvidovre Hospital Herlev Hospital

23 Roche: Strong public-private partnerships I am impressed by Denmark's strong support of public-private partnerships as well as the broad-based interest from all key stakeholders including government, hospitals, universities and industry. Ronald Park, General Manager, Roche Denmark A/S

24 Strong Competencies and High Quality in Clinical Trials, Tests and Research The strong competencies and the high quality in the clinical trials, tests and research in general in Denmark is the reason why Medtronic has established very strong relationships with the highly skilled Danish doctors and scientists. Mette-Marie Harild, Vice President of Nordic and Baltic countries and Poland. Regional office in Copenhagen for all Nordic countries, the Baltics and Poland Center of Research & Innovation at Copenhagen University Hospital, with focus on clinical trials and tests Collaboration with the Cardiac Center at Copenhagen University Hospital, University of Copenhagen and Rehfeld IT-partner on a project to develop intelligent pacemakers

25 MSD: Speed matters in clinical research In Denmark we have no delays in HA/IEC approvals, fast turnaround in signing of contracts and most importantly, rapid and predictable recruitment. Iben Ordrup Christensen, Clinical Research Director, MSD Denmark & Iceland

26 Biogen Idec: Places Strategic Production Site in Danish Biotech Cluster Biogen Idec appreciates the highly skilled Danish workers, but also the Danish ability to cooperate, where employees are permanently contributing with improvements to the production process. ESTHER ALEGRIA, FORMER GENERAL MANAGER & VP MANUFACTURING, BIOGEN IDEC HILLERØD; NOW SENIOR VICE PRESIDENT, GLOBAL PRODUCTION (USA)

27 Tailor-made business solutions for foreign companies Research & Development Unit Strategic Partnerships Production Design Center European Headquarters Distribution Center Sales and Marketing VC Investments in expanding Danish companies

28 Invest in Denmark - We speak business Before Information gathering and analysis Market overview Benchmarking services Mapping potential partners, costumers and service providers Identifying business and funding opportunities Industry insights During Business establishment Practical assistance General advice on legal, financial and corporate structure matters Fact-finding Land and property search Introductory meetings with business clusters and public authorities After Expansion and retention Expansion support Identify new business opportunities Aftercare

29 Denmark s candidacy to host the EMA Brexit -> Relocation of The European Medicines Agency (EMA) which approves and monitors the safety of drugs across Europe The European Banking Authority (EBA) which coordinates EU banking rules

30 Denmark s candidacy to host the EMA 1: World-class research environment Copenhagen offers a world-class research environment. Denmark is the leading country in the EU in terms of number of clinical drug trials per capita. 2: Innovative and vibrant life science cluster Copenhagen is home to an innovative and vibrant life science cluster with Danish and international companies that will provide a highly professional work environment for the European Medicines Agency. Close collaboration between companies, universities and the public health sector provides an ideal ecosystem for innovation. 3: Strong focus on patient safety The Danish healthcare system is characterised by a strong commitment to patient safety and patient involvement. This commitment creates a good setting for the activities of the European Medicines Agency to ensure that all medicines available on the EU market are safe, effective and of high quality.

31 Denmark s candidacy to host the EMA 4: Efficient infrastructure Copenhagen is easily accessible with efficient infrastructure and direct flights to all capitals and major commercial cities of the EU Member States from Copenhagen Airport. 5: High liveability Copenhagen has well-functioning institutions, a high level of public services, a large number of international schools, and the Danes have strong language skills. These conditions make it highly attractive for the employees of the European Medicines Agency and their families to live and work in Denmark.

32